Filing Details

Accession Number:
0000899243-21-047360
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-08 17:05:14
Reporting Period:
2021-12-08
Accepted Time:
2021-12-08 17:05:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1793294 Ppd Inc. PPD () E9
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1618902 Hellman & Friedman Capital Partners Viii (Parallel), L.p. 415 Mission Street, Suite 5700
San Francisco CA 94105
No No Yes No
1618909 Hfcp Viii (Parallel - A), L.p. 415 Mission Street, Suite 5700
San Francisco CA 94105
No No Yes No
1618933 Hellman & Friedman Capital Partners Viii, L.p. 415 Mission Street, Suite 5700
San Francisco CA 94105
No No Yes No
1619367 H&F Executives Viii, L.p. 415 Mission Street, Suite 5700
San Francisco CA 94105
No No Yes No
1621509 H&F Associates Viii, L.p. 415 Mission Street, Suite 5700
San Francisco CA 94105
No No Yes No
1767563 H&F Corporate Investors Viii, Ltd. 415 Mission Street, Suite 5700
San Francisco CA 94105
No No Yes No
1801252 Hellman & Friedman Investors Viii, L.p. 415 Mission Street, Suite 5700
San Francisco CA 94105
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-12-08 52,884,036 $47.50 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-12-08 20,244,387 $47.50 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-12-08 3,630,740 $47.50 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-12-08 359,372 $47.50 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-12-08 35,622,429 $47.50 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-12-08 15,987,409 $47.50 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-12-08 3,021,286 $47.50 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-12-08 934,469 $47.50 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2021-12-08 157,138 $47.50 0 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Footnotes
  1. On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash.
  2. Reflects securities directly held by Hellman & Friedman Capital Partners VII, L.P. ("HFCP VII").
  3. Reflects securities directly held by Hellman & Friedman Capital Partners VII (Parallel), L.P. ("HFCP VII Parallel").
  4. Reflects securities directly held by HFCP VII (Parallel-A), L.P. ("HFCP VII Parallel-A").
  5. Reflects securities directly held by H&F Executives VII, L.P. ("H&F VII Executives", and together with HFCP VII, HFCP VII Parallel and HFCP VII Parallel-A, the "H&F VII Funds").
  6. Reflects securities directly held by Hellman & Friedman Capital Partners VIII, L.P. ("HFCP VIII").
  7. Reflects securities directly held by Hellman & Friedman Capital Partners VIII (Parallel), L.P. ("HFCP VIII Parallel").
  8. Reflects securities directly held by HFCP VIII (Parallel-A), L.P. ("HFCP VIII Parallel-A").
  9. Reflects securities directly held by H&F Executives VIII, L.P. ("H&F VIII Executives").
  10. Reflects securities directly held by H&F Associates VIII, L.P. ("H&F VIII Associates", and together with HFCP VIII, HFCP VIII Parallel, HFCP VIII Parallel-A and H&F VIII Executives, the "H&F VIII Funds").
  11. Hellman & Friedman Investors VII, L.P. ("H&F Investors VII") is the general partner of each of the H&F VII Funds. H&F Corporate Investors VII, Ltd. ("H&F VII") is the general partner of H&F Investors VII. Hellman & Friedman Investors VIII, L.P. ("H&F Investors VIII") is the general partner of each of the H&F VIII Funds. H&F Corporate Investors VIII, Ltd. ("H&F VIII") is the general partner of H&F Investors VIII. A three member board of directors of each of H&F VII and H&F VIII has investment discretion over the shares held by the H&F VII Funds and the H&F VIII Funds, respectively. Allen R. Thorpe, a member of the board of directors of PPD, Inc. is a member of the boards of directors of H&F VII and H&F VIII.